Results 191 to 200 of about 1,591,431 (356)
Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro
Advanced Science, EarlyView.The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel +15 more
wiley +1 more source
Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Advanced Science, EarlyView.Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang +9 more
wiley +1 more source
Advanced Science, EarlyView.This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
Availability of Hib, Pneumococcal, Rotavirus, and HPV vaccines in China: Implication for equity in access to immunization services. [PDF]
PLOS Glob Public HealthGuo L +7 more
europepmc +1 more source
Why Are Drugs More Profitable Than Vaccines? [PDF]
In a simple representative consumer model, vaccines and drug treatments yield the same revenue for a pharmaceutical manufacturer, implying that the firm would have the same incentive to develop either ceteris paribus.
Christopher M. Snyder, Michael Kremer
core
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Advanced Science, EarlyView.Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source